PHAXIAM Therapeutics (XPAR:PHXM) ROC %: -58.65% (As of Sep. 2023)


XPAR:PHXM PHAXIAM Therapeutics SA XPAR:PHXM
38 GF Score
Price €0.10
View Full Analysis

What is PHAXIAM Therapeutics ROC %?

PHAXIAM Therapeutics XPAR:PHXM 38 ROC % is -58.65% as of Sep. 2023. GuruFocus rates XPAR:PHXM with a GF Score™ of 38/100.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. PHAXIAM Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Sep. 2023 was -58.65%.

As of today (2026-06-26), PHAXIAM Therapeutics's WACC % is 0.00%. PHAXIAM Therapeutics's ROC % is 0.00% (calculated using TTM income statement data). PHAXIAM Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


PHAXIAM Therapeutics  (XPAR:PHXM) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, PHAXIAM Therapeutics's WACC % is 0.00%. PHAXIAM Therapeutics's ROC % is 0.00% (calculated using TTM income statement data). PHAXIAM Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


PHAXIAM Therapeutics ROC % Related Terms


PHAXIAM Therapeutics ROC % Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics ROC % Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -299.84 -199.86 -169.30 -157.91 0.00

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -181.47 -115.53 110.61 0.00 -58.65
XPAR:PHXM
38GF Score
PHAXIAM Therapeutics SA XPAR:PHXM
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics ROC % Calculation

PHAXIAM Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-27.147 * ( 1 - 100% )/( (32.51 + 9.681)/ 2 )
=-0/21.0955
=0.00 %

where

PHAXIAM Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-23.028 * ( 1 - 0% )/( (39.265 + 0)/ 1 )
=-23.028/39.265
=-58.65 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -58.65% mean?
PHAXIAM Therapeutics (XPAR:PHXM) has a ROC % of -58.65% as of Sep. 2023. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on PHAXIAM Therapeutics and its competitors.
Is PHAXIAM Therapeutics' ROC % too high?
PHAXIAM Therapeutics' current ROC % is -58.65%. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' ROC % compare to VRTX and REGN?
PHAXIAM Therapeutics' ROC % of -58.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on PHAXIAM Therapeutics and its competitors. PHAXIAM Therapeutics's current ROC % is -58.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (XPAR:PHXM) has a current ROC % of -58.65%. The current ROC % is -58.65%. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For PHAXIAM Therapeutics (XPAR:PHXM), the current ROC % is -58.65% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for XPAR:PHXM

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price